vs
ARTIVION, INC.（AORT）とPREFORMED LINE PRODUCTS CO（PLPC）の財務データ比較。上の社名をクリックして会社を切り替えられます
PREFORMED LINE PRODUCTS COの直近四半期売上が大きい（$173.1M vs $116.0M、ARTIVION, INC.の約1.5倍）。PREFORMED LINE PRODUCTS COの純利益率が高く（4.9% vs 2.1%、差は2.8%）。ARTIVION, INC.の前年同期比売上増加率が高い（19.2% vs 3.6%）。PREFORMED LINE PRODUCTS COの直近四半期フリーキャッシュフローが多い（$11.8M vs $-7.9M）。過去8四半期でPREFORMED LINE PRODUCTS COの売上複合成長率が高い（10.8% vs 9.1%）
Artivion, Inc.は心血管移植向けの極低温保存した人体組織の流通、及び医療機器の開発を行う医療企業です。同社の製品には、余分な細胞物質と抗原を除去する処理を施した人間の心臓弁、手術用接着剤BioGlueなどがあり、臨床現場のニーズに応えています。
プリフォームド・ライン・プロダクツ社（PLPC）は、送配電、通信、再生可能エネルギーインフラ分野向けのエンジニアリングハードウェアや部品を設計・製造・供給し、世界各国の事業者にネットワークの信頼性と業務効率を高めるソリューションを提供している。
AORT vs PLPC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $116.0M | $173.1M |
| 純利益 | $2.4M | $8.4M |
| 粗利率 | 63.1% | 29.8% |
| 営業利益率 | 9.2% | 6.8% |
| 純利益率 | 2.1% | 4.9% |
| 売上前年比 | 19.2% | 3.6% |
| 純利益前年比 | 114.7% | -19.3% |
| EPS（希薄化後） | $0.06 | $1.72 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $116.0M | $173.1M | ||
| Q3 25 | $113.4M | $178.1M | ||
| Q2 25 | $113.0M | $169.6M | ||
| Q1 25 | $99.0M | $148.5M | ||
| Q4 24 | $97.3M | $167.1M | ||
| Q3 24 | $95.8M | $147.0M | ||
| Q2 24 | $98.0M | $138.7M | ||
| Q1 24 | $97.4M | $140.9M |
| Q4 25 | $2.4M | $8.4M | ||
| Q3 25 | $6.5M | $2.6M | ||
| Q2 25 | $1.3M | $12.7M | ||
| Q1 25 | $-505.0K | $11.5M | ||
| Q4 24 | $-16.5M | $10.5M | ||
| Q3 24 | $-2.3M | $7.7M | ||
| Q2 24 | $-2.1M | $9.4M | ||
| Q1 24 | $7.5M | $9.6M |
| Q4 25 | 63.1% | 29.8% | ||
| Q3 25 | 65.6% | 29.7% | ||
| Q2 25 | 64.7% | 32.7% | ||
| Q1 25 | 64.2% | 32.8% | ||
| Q4 24 | 63.2% | 33.3% | ||
| Q3 24 | 63.7% | 31.1% | ||
| Q2 24 | 64.6% | 31.9% | ||
| Q1 24 | 64.6% | 31.3% |
| Q4 25 | 9.2% | 6.8% | ||
| Q3 25 | 11.1% | 7.4% | ||
| Q2 25 | 7.4% | 10.1% | ||
| Q1 25 | 2.2% | 8.8% | ||
| Q4 24 | 2.7% | 10.5% | ||
| Q3 24 | 4.6% | 7.1% | ||
| Q2 24 | 6.6% | 8.1% | ||
| Q1 24 | 26.0% | 8.2% |
| Q4 25 | 2.1% | 4.9% | ||
| Q3 25 | 5.7% | 1.5% | ||
| Q2 25 | 1.2% | 7.5% | ||
| Q1 25 | -0.5% | 7.8% | ||
| Q4 24 | -16.9% | 6.3% | ||
| Q3 24 | -2.4% | 5.2% | ||
| Q2 24 | -2.2% | 6.8% | ||
| Q1 24 | 7.7% | 6.8% |
| Q4 25 | $0.06 | $1.72 | ||
| Q3 25 | $0.13 | $0.53 | ||
| Q2 25 | $0.03 | $2.56 | ||
| Q1 25 | $-0.01 | $2.33 | ||
| Q4 24 | $-0.40 | $2.13 | ||
| Q3 24 | $-0.05 | $1.54 | ||
| Q2 24 | $-0.05 | $1.89 | ||
| Q1 24 | $0.18 | $1.94 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $64.9M | — |
| 総負債低いほど良い | $215.1M | $38.3M |
| 株主資本純資産 | $448.2M | $475.5M |
| 総資産 | $884.8M | $653.6M |
| 負債/資本比率低いほどレバレッジが低い | 0.48× | 0.08× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $64.9M | — | ||
| Q3 25 | $73.4M | — | ||
| Q2 25 | $53.5M | — | ||
| Q1 25 | $37.7M | — | ||
| Q4 24 | $53.5M | — | ||
| Q3 24 | $56.2M | — | ||
| Q2 24 | $55.0M | — | ||
| Q1 24 | $51.1M | — |
| Q4 25 | $215.1M | $38.3M | ||
| Q3 25 | $214.9M | $36.0M | ||
| Q2 25 | $215.6M | $31.8M | ||
| Q1 25 | $314.7M | $29.1M | ||
| Q4 24 | $314.3M | $20.8M | ||
| Q3 24 | $314.0M | $27.2M | ||
| Q2 24 | $313.6M | $31.6M | ||
| Q1 24 | $313.3M | $55.0M |
| Q4 25 | $448.2M | $475.5M | ||
| Q3 25 | $438.7M | $466.3M | ||
| Q2 25 | $419.9M | $460.7M | ||
| Q1 25 | $294.3M | $435.8M | ||
| Q4 24 | $276.2M | $422.3M | ||
| Q3 24 | $304.7M | $429.0M | ||
| Q2 24 | $295.1M | $416.2M | ||
| Q1 24 | $295.0M | $413.4M |
| Q4 25 | $884.8M | $653.6M | ||
| Q3 25 | $857.7M | $644.6M | ||
| Q2 25 | $838.4M | $631.5M | ||
| Q1 25 | $791.2M | $592.5M | ||
| Q4 24 | $789.1M | $573.9M | ||
| Q3 24 | $803.1M | $592.0M | ||
| Q2 24 | $789.5M | $572.6M | ||
| Q1 24 | $784.0M | $586.1M |
| Q4 25 | 0.48× | 0.08× | ||
| Q3 25 | 0.49× | 0.08× | ||
| Q2 25 | 0.51× | 0.07× | ||
| Q1 25 | 1.07× | 0.07× | ||
| Q4 24 | 1.14× | 0.05× | ||
| Q3 24 | 1.03× | 0.06× | ||
| Q2 24 | 1.06× | 0.08× | ||
| Q1 24 | 1.06× | 0.13× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.6M | $21.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $-7.9M | $11.8M |
| FCFマージンFCF / 売上 | -6.9% | 6.8% |
| 設備投資強度設備投資 / 売上 | 23.7% | 5.9% |
| キャッシュ転換率営業CF / 純利益 | 8.06× | 2.60× |
| 直近12ヶ月FCF直近4四半期 | $839.0K | $33.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $19.6M | $21.9M | ||
| Q3 25 | $22.3M | $18.9M | ||
| Q2 25 | $15.0M | $26.9M | ||
| Q1 25 | $-17.0M | $5.7M | ||
| Q4 24 | $10.1M | $24.1M | ||
| Q3 24 | $11.5M | $9.4M | ||
| Q2 24 | $6.1M | $28.3M | ||
| Q1 24 | $-5.5M | $5.8M |
| Q4 25 | $-7.9M | $11.8M | ||
| Q3 25 | $17.7M | $8.3M | ||
| Q2 25 | $11.7M | $18.6M | ||
| Q1 25 | $-20.6M | $-5.3M | ||
| Q4 24 | $8.7M | $20.6M | ||
| Q3 24 | $7.8M | $5.8M | ||
| Q2 24 | $3.6M | $24.6M | ||
| Q1 24 | $-9.1M | $1.8M |
| Q4 25 | -6.9% | 6.8% | ||
| Q3 25 | 15.6% | 4.7% | ||
| Q2 25 | 10.4% | 10.9% | ||
| Q1 25 | -20.8% | -3.6% | ||
| Q4 24 | 9.0% | 12.3% | ||
| Q3 24 | 8.2% | 3.9% | ||
| Q2 24 | 3.7% | 17.7% | ||
| Q1 24 | -9.3% | 1.3% |
| Q4 25 | 23.7% | 5.9% | ||
| Q3 25 | 4.1% | 6.0% | ||
| Q2 25 | 2.9% | 4.9% | ||
| Q1 25 | 3.7% | 7.4% | ||
| Q4 24 | 1.5% | 2.1% | ||
| Q3 24 | 3.8% | 2.4% | ||
| Q2 24 | 2.6% | 2.7% | ||
| Q1 24 | 3.7% | 2.8% |
| Q4 25 | 8.06× | 2.60× | ||
| Q3 25 | 3.42× | 7.21× | ||
| Q2 25 | 11.16× | 2.12× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 3.02× | ||
| Q1 24 | -0.73× | 0.60× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
PLPC
セグメントデータなし
